Patent ID: 8841081

Claim:
A method of treating metastatic stage prostate cancer in a subject, the method comprising: identifying a subject with metastatic stage prostate cancer comprising measuring the subject's baseline serum alkaline phosphatase (S-ALP) level; and reducing the subject's S-ALP level with respect to the baseline level by administering an initial dose of degarelix ranging from about 160 to about 320 mg to the subject; and administering at least one maintenance dose of degarelix ranging from about 60 mg to about 160 mg to the subject, wherein the at least one maintenance dose is administered approximately 20 days to 36 days, after the previous dose of degarelix for a duration of treatment ranging from 20 days to 450 days; and further, wherein the S-ALP level is reduced for the duration of treatment relative to the initial S-ALP level measured at the start of treatment.